We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aldagen Adds Three Clinical Sites to its Critical Limb Ischemia Study
News

Aldagen Adds Three Clinical Sites to its Critical Limb Ischemia Study

Aldagen Adds Three Clinical Sites to its Critical Limb Ischemia Study
News

Aldagen Adds Three Clinical Sites to its Critical Limb Ischemia Study

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aldagen Adds Three Clinical Sites to its Critical Limb Ischemia Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aldagen, Inc. has announced the addition of three new sites for its clinical trial of ALD-301 for the treatment of critical limb ischemia.

The three additional sites are Duke University Medical Center (Durham, NC), Indiana University (Indianapolis, IN) and Saint Joseph’s Research Institute (Atlanta, GA). These sites join Texas Heart Institute at St. Luke’s Episcopal Hospital in Houston, Texas, which was the original site on the study.

Dr. Rob Mitchell will be the principal investigator at Duke University Medical Center. Dr. Michael Murphy and Dr. Keith March are the co-lead investigators at Indiana University. Dr. Nicolas Chronos is the principal investigator at Saint Joseph’s Research Institute. The co-lead investigators at Texas Heart Institute on the study are Dr. Emerson Perin and Dr. James Willerson.

Aldagen’s clinical trial will involve 20 patients, all of which will have their own bone marrow extracted. Ten patients will receive multiple injections of the bone marrow directly into muscle in the ischemic leg and ten patients will receive multiple injections of ALD-301.

The patients will be monitored for up to six months with a primary endpoint at three months. Endpoints will include safety and the ability of therapy to reduce rest pain, increase skin surface oxygen pressure and improve ulcer healing.

“We are very excited to have such prestigious institutions join this study, which is the first clinical study in the United States to use purified stem cells for the treatment of critical limb ischemia. We believe that ALD-301 has the potential to offer CLI patients a new therapeutic option,” said Tom Amick, Chairman and Chief Executive Officer of Aldagen.

Advertisement